Emergent BioSolutions Inc. (0IGA.L)
USD 8.5
(-3.22%)
USD 8.5
(-3.22%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 328.9 Million USD | -6.51% |
| 2022 | 351.8 Million USD | 0.29% |
| 2021 | 350.8 Million USD | 14.27% |
| 2020 | 307 Million USD | 37.98% |
| 2019 | 222.5 Million USD | 8.11% |
| 2018 | 205.8 Million USD | 44.11% |
| 2017 | 142.81 Million USD | 92.98% |
| 2016 | 74 Million USD | -3.81% |
| 2015 | 76.93 Million USD | 17.15% |
| 2014 | 65.67 Million USD | 348.5% |
| 2013 | 14.64 Million USD | -3.42% |
| 2012 | 15.16 Million USD | 3.41% |
| 2011 | 14.66 Million USD | 15.24% |
| 2010 | 12.72 Million USD | -5.91% |
| 2009 | 13.52 Million USD | -31.46% |
| 2008 | 19.72 Million USD | 16.75% |
| 2007 | 16.89 Million USD | -31.65% |
| 2006 | 24.72 Million USD | 50.36% |
| 2005 | 16.44 Million USD | 24.05% |
| 2004 | 13.25 Million USD | 0.0% |
| 2002 | - USD | -100.0% |
| 2001 | 307 Million USD | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 317.5 Million USD | -4.77% |
| 2024 Q1 | 333.4 Million USD | 1.37% |
| 2023 Q2 | 354.3 Million USD | -3.7% |
| 2023 Q4 | 328.9 Million USD | -7.12% |
| 2023 FY | 328.9 Million USD | -6.51% |
| 2023 Q1 | 367.9 Million USD | 4.58% |
| 2023 Q3 | 354.1 Million USD | -0.06% |
| 2022 FY | 351.8 Million USD | 0.29% |
| 2022 Q4 | 351.8 Million USD | -35.6% |
| 2022 Q2 | 425.5 Million USD | 6.19% |
| 2022 Q3 | 546.3 Million USD | 28.39% |
| 2022 Q1 | 400.7 Million USD | 14.22% |
| 2021 FY | 350.8 Million USD | 14.27% |
| 2021 Q1 | 406.5 Million USD | 32.41% |
| 2021 Q2 | 386.4 Million USD | -4.94% |
| 2021 Q3 | 364.6 Million USD | -5.64% |
| 2021 Q4 | 350.8 Million USD | -3.78% |
| 2020 Q1 | 248.1 Million USD | 11.51% |
| 2020 FY | 307 Million USD | 37.98% |
| 2020 Q4 | 307 Million USD | 13.66% |
| 2020 Q3 | 270.1 Million USD | 14.35% |
| 2020 Q2 | 236.2 Million USD | -4.8% |
| 2019 Q3 | 230.2 Million USD | -0.78% |
| 2019 Q4 | 222.5 Million USD | -3.34% |
| 2019 Q2 | 232 Million USD | 9.95% |
| 2019 FY | 222.5 Million USD | 8.11% |
| 2019 Q1 | 211 Million USD | 2.53% |
| 2018 Q2 | 139.37 Million USD | -10.2% |
| 2018 Q1 | 155.19 Million USD | 8.67% |
| 2018 FY | 205.8 Million USD | 44.11% |
| 2018 Q3 | 125.74 Million USD | -9.78% |
| 2018 Q4 | 205.8 Million USD | 63.66% |
| 2017 FY | 142.81 Million USD | 92.98% |
| 2017 Q4 | 142.81 Million USD | 107.31% |
| 2017 Q3 | 68.88 Million USD | -2.33% |
| 2017 Q2 | 70.52 Million USD | -0.29% |
| 2017 Q1 | 70.73 Million USD | -4.42% |
| 2016 Q4 | 74 Million USD | -8.82% |
| 2016 FY | 74 Million USD | -3.81% |
| 2016 Q1 | 88.2 Million USD | 14.64% |
| 2016 Q2 | 96.67 Million USD | 9.61% |
| 2016 Q3 | 81.16 Million USD | -16.05% |
| 2015 Q3 | 80.07 Million USD | -5.48% |
| 2015 Q1 | 82.13 Million USD | 25.06% |
| 2015 Q4 | 76.93 Million USD | -3.91% |
| 2015 FY | 76.93 Million USD | 17.15% |
| 2015 Q2 | 84.7 Million USD | 3.13% |
| 2014 Q2 | 66.03 Million USD | -7.35% |
| 2014 Q1 | 71.26 Million USD | 386.7% |
| 2014 FY | 65.67 Million USD | 348.5% |
| 2014 Q4 | 65.67 Million USD | 5.02% |
| 2014 Q3 | 62.53 Million USD | -5.3% |
| 2013 Q4 | 14.64 Million USD | -10.3% |
| 2013 Q1 | 22.14 Million USD | 46.09% |
| 2013 Q2 | 18.58 Million USD | -16.1% |
| 2013 FY | 14.64 Million USD | -3.42% |
| 2013 Q3 | 16.32 Million USD | -12.15% |
| 2012 FY | 15.16 Million USD | 3.41% |
| 2012 Q3 | 18.24 Million USD | 13.97% |
| 2012 Q2 | 16 Million USD | -7.57% |
| 2012 Q1 | 17.31 Million USD | 18.13% |
| 2012 Q4 | 15.16 Million USD | -16.9% |
| 2011 FY | 14.66 Million USD | 15.24% |
| 2011 Q4 | 14.66 Million USD | -18.45% |
| 2011 Q3 | 17.97 Million USD | 4.15% |
| 2011 Q2 | 17.26 Million USD | -22.11% |
| 2011 Q1 | 22.16 Million USD | 74.21% |
| 2010 Q4 | 12.72 Million USD | -26.55% |
| 2010 Q1 | 17.08 Million USD | 26.33% |
| 2010 Q2 | 17.11 Million USD | 0.2% |
| 2010 Q3 | 17.32 Million USD | 1.19% |
| 2010 FY | 12.72 Million USD | -5.91% |
| 2009 FY | 13.52 Million USD | -31.46% |
| 2009 Q4 | 13.52 Million USD | -14.51% |
| 2009 Q3 | 15.81 Million USD | 12.63% |
| 2009 Q2 | 14.04 Million USD | -0.78% |
| 2009 Q1 | 14.15 Million USD | -28.26% |
| 2008 Q2 | 18.87 Million USD | 0.47% |
| 2008 Q4 | 19.72 Million USD | 12.63% |
| 2008 Q1 | 18.79 Million USD | 11.2% |
| 2008 FY | 19.72 Million USD | 16.75% |
| 2008 Q3 | 17.51 Million USD | -7.22% |
| 2007 Q3 | 25.62 Million USD | -11.29% |
| 2007 Q2 | 28.88 Million USD | 7.44% |
| 2007 Q4 | 16.89 Million USD | -34.06% |
| 2007 Q1 | 26.88 Million USD | 8.75% |
| 2007 FY | 16.89 Million USD | -31.65% |
| 2006 Q4 | 24.72 Million USD | -11.92% |
| 2006 FY | 24.72 Million USD | 50.36% |
| 2006 Q3 | 28.06 Million USD | 0.0% |
| 2005 Q4 | 16.44 Million USD | 0.0% |
| 2005 FY | 16.44 Million USD | 24.05% |
| 2004 FY | 13.25 Million USD | 0.0% |
| 2004 Q4 | 13.25 Million USD | 0.0% |
| 2002 FY | - USD | -100.0% |
| 2001 Q4 | 350.8 Million USD | 0.0% |
| 2001 FY | 307 Million USD | 0.0% |
| 2000 Q4 | 351.8 Million USD | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Editas Medicine, Inc. | - USD | -Infinity% |
| Dynavax Technologies Corporation | 53.29 Million USD | -517.189% |
| Supernus Pharmaceuticals, Inc. | 77.4 Million USD | -324.891% |
| Perrigo Company plc | 1.14 Billion USD | 71.172% |
| Illumina, Inc. | 587 Million USD | 43.969% |
| Thermo Fisher Scientific Inc. | 5.08 Billion USD | 93.536% |
| Iovance Biotherapeutics, Inc. | 10.37 Million USD | -3071.037% |
| Walgreens Boots Alliance, Inc. | 8.32 Billion USD | 96.047% |
| IQVIA Holdings Inc. | - USD | -Infinity% |
| Heron Therapeutics, Inc. | 42.11 Million USD | -681.05% |
| Regeneron Pharmaceuticals, Inc. | 2.58 Billion USD | 87.254% |
| Unity Biotechnology, Inc. | - USD | -Infinity% |
| Waters Corporation | 516.23 Million USD | 36.289% |
| Biogen Inc. | 2.52 Billion USD | 86.987% |
| Sangamo Therapeutics, Inc. | - USD | -Infinity% |
| Evolus, Inc. | 10.99 Million USD | -2890.544% |
| Adicet Bio, Inc. | - USD | -Infinity% |
| Cara Therapeutics, Inc. | 2.82 Million USD | -11558.986% |
| bluebird bio, Inc. | 22.91 Million USD | -1335.054% |
| Esperion Therapeutics, Inc. | 65.62 Million USD | -401.196% |
| FibroGen, Inc. | 41.56 Million USD | -691.291% |
| Agilent Technologies, Inc. | 1.03 Billion USD | 68.099% |
| Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Homology Medicines, Inc. | - USD | -Infinity% |
| Geron Corporation | - USD | -Infinity% |
| Alnylam Pharmaceuticals, Inc. | 89.14 Million USD | -268.945% |
| Amicus Therapeutics, Inc. | 59.69 Million USD | -450.958% |
| Myriad Genetics, Inc. | 20.1 Million USD | -1536.318% |
| Viking Therapeutics, Inc. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | - USD | -Infinity% |
| Zoetis Inc. | 2.56 Billion USD | 87.172% |
| Abeona Therapeutics Inc. | -2.44 Million USD | 13557.447% |
| Mettler-Toledo International Inc. | 385.86 Million USD | 14.763% |
| BioMarin Pharmaceutical Inc. | 1.1 Billion USD | 70.294% |
| Vertex Pharmaceuticals Incorporated | 738.8 Million USD | 55.482% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Ionis Pharmaceuticals, Inc. | 28.42 Million USD | -1057.08% |
| Atara Biotherapeutics, Inc. | 9.7 Million USD | -3288.626% |
| Verastem, Inc. | - USD | -Infinity% |
| Nektar Therapeutics | 16.1 Million USD | -1942.73% |
| Axsome Therapeutics, Inc. | 15.13 Million USD | -2073.109% |
| Aclaris Therapeutics, Inc. | - USD | -Infinity% |
| Sarepta Therapeutics, Inc. | 322.85 Million USD | -1.871% |
| OPKO Health, Inc. | 65.69 Million USD | -400.632% |
| Exelixis, Inc. | 17.32 Million USD | -1798.632% |
| Neurocrine Biosciences, Inc. | 38.3 Million USD | -758.747% |
| Corcept Therapeutics Incorporated | 7.73 Million USD | -4154.851% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| uniQure N.V. | 12.02 Million USD | -2635.363% |
| Imunon, Inc. | - USD | -Infinity% |
| Blueprint Medicines Corporation | 21.22 Million USD | -1449.734% |
| Insmed Incorporated | 83.24 Million USD | -295.085% |
| Halozyme Therapeutics, Inc. | 127.6 Million USD | -157.757% |
| Agios Pharmaceuticals, Inc. | 19.07 Million USD | -1624.156% |
| TG Therapeutics, Inc. | 39.82 Million USD | -725.905% |
| Incyte Corporation | 62.97 Million USD | -422.296% |